Bevacizumab-induced laryngeal necrosis.

Hartl, D M

Bevacizumab-induced laryngeal necrosis. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology Jan 2012 - 276-278 p. digital

Publication Type: Case Reports; Letter

1569-8041

10.1093/annonc/mdr515 doi


Adenocarcinoma--drug therapy
Antibodies, Monoclonal, Humanized--adverse effects
Antineoplastic Agents--adverse effects
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bevacizumab
Carboplatin--administration & dosage
Cisplatin--administration & dosage
Clinical Trials, Phase I as Topic
Deoxycytidine--administration & dosage
Female
Glutamates--administration & dosage
Guanine--administration & dosage
Humans
Laryngeal Diseases--chemically induced
Lung Neoplasms--drug therapy
Middle Aged
Necrosis--chemically induced
Neoplasm Recurrence, Local--drug therapy
Paclitaxel--administration & dosage
Pemetrexed
Tubulin Modulators--administration & dosage
Gemcitabine